Akebia Announces Presentations at the Upcoming American

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Akebia Announces Presentations at the Upcoming American Society of Nephrology Kidney Week 2015 Annual Meeting

CAMBRIDGE, Mass., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Akebia Therapeutics, Inc. (NASDAQ: AKBA ), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced that data from the vadadustat (formerly AKB-6548) development program will be presented at the upcoming American Society of Nephrology (ASN) Kidney Week 2015 annual meeting in San Diego, California from November 3-8, 2015.

Late-Breaker Poster Presentation:
   
Saturday, November 7, 2015, 10:00 AM - 12:00 PM
Title:  Vadadustat, a Novel Oral Treatment for Anemia of Chronic Kidney Disease, Maintains Stable Hemoglobin Levels in Dialysis Patient Converting from Erythropoiesis-Stimulating Agents (Abstract Program #SA-PO1110)
Session Title: Late-Breaking Clinical Trial Posters
Location: Exhibit Hall
   
Oral Presentation:
   
Thursday, November 5, 2015, 4:30 PM - 6:30 PM, Presentation 5:54 PM 
Title:    Hemoglobin (Hb) Response in a Phase 2b Study of AKB-6548 for the Treatment of Anemia in Patients with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) (Abstract Program #TH-OR038)
Session Title: Clinical Trials in CKD: Pursuing a New Horizon
Location: Room 25 
Poster Sessions:
   
Thursday, November 5, 2015, 10:00 AM - 12:00 PM
Title:    Vadadustat Demonstrates Controlled Hemoglobin Response in a Phase 2b Study for the Treatment of Anemia in Patients with Non-Dialysis Dependent Chronic Kidney Disease (Abstract Program #TH-PO649)
Session Title: CKD: Clinical Trials
Location: Exhibit Hall
   
Saturday, November 7, 2015, 10:00 AM - 12:00 PM
Title:  Dose Exposure Relationship of Vadadustat is Independent of the Level of Renal Function (Abstract Program #SA-PO537)
Session Title: Drug Pharmacokinetics and Pharmacogenomics in CKD
Location: Exhibit Hall
 
Collaborative Poster Session Details:
   
Thursday, November 5, 2015, 10:00 AM - 12:00 PM
Title:  The Effect of Altitude on Erythropoiesis-Stimulating Agent Dose, Hemoglobin Level, and Mortality in Hemodialysis Patients (Abstract Program #TH-PO936)
Session Title: Dialysis: Epidemiology, Outcomes, and Clinical Trials: Noncardiovascular - I
Location: Exhibit Hall
Collaboration with Davita Clinical Research
   
Saturday, November 7, 2015, 10:00 AM - 12:00 PM
Title:    Erythropoietin-Stimulating Agent (ESA) Hyporesponse (ESAhr) Is Associated with Persistently Elevated Mortality Among Hemodialysis (HD) Patients (Abstract Program #SA-PO800)
Session Title: Dialysis: Anemia and Iron Metabolism
Location: Exhibit Hall
Collaboration with Davita Clinical Research
   
Saturday, November 7, 2015, 10:00 AM - 12:00 PM
Title:  Variability in Hemoglobin (Hb) Levels in Hemodialysis (HD) Patients in the Current Era (Abstract Program #SA-PO824)
Session Title: Dialysis: Anemia and Iron Metabolism
Location: Exhibit Hall
Collaboration with Chronic Disease Research Group (CDRG)

The clinical posters will be available on Akebia's website ( www.akebia.com ) in the Media section under the Publications tab.

About Vadadustat (Formerly AKB-6548)

Vadadustat is an oral therapy currently in development for the treatment of anemia related to chronic kidney disease (CKD). Vadadustat is designed to stabilize HIF, a transcription factor that regulates the expression of genes involved with red blood cell (RBC) production in response to changes in oxygen levels, by inhibiting the hypoxia-inducible factor prolyl hydroxylase (HIF-PH) enzyme. Vadadustat exploits the same mechanism of action used by the body to naturally adapt to lower oxygen availability associated with a moderate increase in altitude. At higher altitudes, the body responds to lower oxygen availability with increased production of HIF, which coordinates the interdependent processes of iron mobilization and erythropoietin (EPO) production to increase RBC production and, ultimately, improve oxygen delivery.

As a HIF stabilizer with best-in-class potential, vadadustat raises hemoglobin levels predictably and sustainably, with a dosing regimen that allows for a gradual and controlled titration. Vadadustat has been shown to improve iron mobilization, potentially eliminating the need for intravenous iron administration and reducing the overall need for iron supplementation.

About Anemia Related to CKD

Approximately 30 million people in the United States have CKD, with an estimated 1.8 million of these patients suffering from anemia. Anemia results from the body's inability to coordinate RBC production in response to lower oxygen levels due to the progressive loss of kidney function, which occurs in patients with CKD. Left untreated, anemia significantly accelerates patients' overall deterioration of health with increased morbidity and mortality. Renal anemia is currently treated with injectable rESAs, which are associated with inconsistent hemoglobin responses and well-documented safety risks.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. The company has completed Phase 2 development of its lead product candidate, vadadustat, an oral therapy for the treatment of anemia related to CKD in both non-dialysis and dialysis patients.

Forward-Looking Statements

This press release includes forward-looking statements. Such forward-looking statements include those about Akebia's strategy, future plans and prospects, including statements regarding the potential indications, dosing and benefits of vadadustat, and the presentation of data at the ASN Kidney Week 2015 annual meeting. The words "anticipate," "appear," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including the risk that existing preclinical and clinical data may not be predictive of the results of ongoing or later clinical trials; the ability of Akebia to successfully complete the clinical development of vadadustat; the funding required to develop Akebia's product candidates and operate the company, and the actual expenses associated therewith; the cost of the Phase 3 program and the availability of financing to cover such cost; the timing and content of decisions made by the FDA, EMA and other regulatory authorities; the actual time it takes to prepare for and initiate the Phase 3 program, including initiating sites and enrolling patients; the success of competitors in developing product candidates for diseases for which Akebia is currently developing its product candidates; and Akebia's ability to obtain, maintain and enforce patent and other intellectual property protection for vadadustat. Other risks and uncertainties include those identified under the heading "Risk Factors" in Akebia's Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, and other filings that Akebia may make with the Securities and Exchange Commission in the future. Akebia does not undertake, and specifically disclaims, any obligation to update any forward-looking statements contained in this press release.

Investors: Ed Joyce (617) 844-6130 Media: Argot Partners Eliza Schleifstein (917) 763-8106

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 211

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 254

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 138

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 356

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 183

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 177

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 211

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 225

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading

Top 5 Most Recently Viewed Articles

Impressive Financial Growth for Caris Life Sciences in Q2 2025

Updated Category News Views 262

Caris Life Sciences Achieves Significant Growth in Financial Results Today, Caris Life Sciences, Inc. (NASDAQ: CAI) reported remarkable financial results, highlighting a 81.3% increase in total revenue year-over-year for the second quarter of 2025. This substantial growth showcases the company's resilience and innovative approach in the ever-evolving healthcare landscape....

Continue Reading
What to Expect from Globus Maritime's Upcoming Earnings Report

Updated Category News Views 253

Anticipating Globus Maritime's Earnings Report Globus Maritime (NASDAQ: GLBS) is gearing up to unveil its quarterly earnings report soon, and investors are eager to gain insight into the company’s financial performance. This report will be a crucial indicator of the company's trajectory as it navigates the ever-changing maritime industry. Analyst Expectations for...

Continue Reading
Discover Exciting Savings with Haoqi E-Bikes This Sale

Updated Category News Views 187

Haoqi E-Bikes Launches Exciting Black Friday Sale With a profound appreciation for family and the great outdoors, Haoqi E-Bikes is thrilled to reveal its noteworthy promotion on the highly sought-after Cheetah Dual Battery Full Suspension E-Bike. From an initial launch date, the brand will provide an incredible discount of $1101 on the Cheetah model to promote outdoor...

Continue Reading
3 Unstoppable Dividend Stocks for Income Investors

Updated Category News Views 125

Finding Reliable Dividend Stocks For investors seeking income, stocks that offer stability and dependable dividends are often the preferred choice. It's generally unwise to invest in companies with uncertain futures that might reduce their dividends. Instead, savvy investors focus on resilient dividend stocks that promise steady returns and growth over time. A Dividend...

Continue Reading
Certification Boosts Aviation Capital's Boeing 737-10 Prospects

Updated Category News Views 115

Nothing like a green light from the FAA to put a little extra swagger in an aircraft lessor's step, and that's exactly what's happening with Aviation Capital Group (ACG) and their big bet on Boeing's 737-10. It's like the champagne just got popped! This milestone is no minor hurdle. We're talking about the largest addition to the 737 MAX family finally giving an official...

Continue Reading